SkinBioTherapeutics (GB:SBTX) has released an update.
SkinBioTherapeutics reports successful results from its AxisBiotix Acne food supplement consumer study, with 84% of participants noting improved spot appearance and 77% experiencing reduced pain. With 89% of participants willing to continue using the product, the company is now focusing on the final product formulation and commercialization for the growing global acne treatment market. The positive outcome of the study indicates potential for the product to be a new player in a market valued at $9.4 billion.
For further insights into GB:SBTX stock, check out TipRanks’ Stock Analysis page.
